guild wars 2,guild wars 2 gold,guild wars 2 power leveling,www.guildwars2vip.com,Guild Wars 2 Gold,GW2 Gold,Guild Wars 2 Power Leveling,www.guildwars2casa.com,WoW Gold,Cheap WoW Gold,Buy WoW Gold,www.wowgoldapp.com,FFXI Gil,Final Fantasy XI Gil,Final Fantasy XI,www.ffximvp.com,Air Jordans,Nike Air Max,LeBron James Shoes,www.elvashoes.com,Aion Kinah,Aion Gold,Aion Kina,www.aionmvp.com,Runescape Gold,RS Gold,Runescape,www.runescapecasa.com,diablo 3 gold,diablo iii gold,diablo 3 power leveling,www.diablo3s.com,Adidas Predator,Adidas Adipure,Adidas F50 Adizero,www.shoesrar.com,Replica Handbags,Replica Watches,www.replica.im,Replica Handbags,Replica Bags,www.BadgesTacking.com,Fashion Clothing,Fashion Clothes,www.Schnaeder.com,WoW Gold,Jewelry Stores,Jewellery UK Online,www.jahngalley.org,Wedding Dresses,Evening Dresses,www.ecoeasycontest.com
 
Nuclear Medicine
Nuclear Pharmacy
Education
Jobs
Advertise
Photo Gallery
Blog
Contact Us
Sign in | Create an Account  
Take A Look Inside Nuclear Pharmacies
WHY ADVERTISE WITH US?
 
 Post Jobs - Targeted community
 Advertise - Promote your company
 Access Resumes - View profiles
 
HOT JOBS
 
 
Search Nuclear Pharmacy Jobs
Keyword:
Location:
 View Nuclear Pharmacies Nationwide
Blogs
 
Cardinal Health Nuclear Pharmacy will manufacture and distribute Amyvid
, 19-June-2012

DUBLIN, Ohio, June 1, 2012 /PRNewswire/ -- Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012. Cardinal Health to Provide Access to New Imaging Agent That Aids in Evaluation of Patients With Suspected Alzheimer's Disease and Other Causes of Cognitive Decline.

Amyvid works by binding to amyloid plaques, one of the necessary pathological features of Alzheimer's Disease,[1,2,3] and is detected using PET scan images of the brain.[4] A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.[1,5] A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.[3,4,6]

It is important to note that Amyvid is an adjunct to other diagnostic evaluations, and a positive Amyvid scan does not establish a diagnosis of Alzheimer's Disease or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or when used to monitor responses to therapies.[4]

Radioactive agents like Amyvid are often likened to "shrinking ice cubes," because once they are manufactured, their radioactivity quickly decays. Amyvid loses over half of its radioactivity every two hours, so the sites that manufacture it need to be located in close proximity to hospitals and health centers that will use it.

Cardinal Health will manufacture and distribute Amyvid at seven sites throughout the U.S. beginning in June 2012, with a potential expansion to 12 locations by the end of the calendar year.

Through its broad nationwide network of manufacturing facilities and radiopharmacies, Cardinal Health's Nuclear Pharmacy Services business can reach more than 90 percent of all U.S. hospitals within three hours' time - empowering the company to play a critical role in quickly expanding access to imaging agents. The company's sophisticated radiopharmaceutical manufacturing infrastructure, broad nuclear pharmacy scale, comprehensive fleet and logistics capabilities also enable it to play a critical role in supporting clinical trials of both proprietary and non-proprietary imaging agents.

"We are excited to play an important role in efficiently and safely getting this innovative imaging agent in the hands of clinicians and imaging professionals so they can expand their arsenal of tools to help in the evaluation of Alzheimer's Disease and other causes of cognitive decline," said John Rademacher, president of Cardinal Health's Nuclear Pharmacy Services business. "We consider it a privilege to have the opportunity to manufacture and distribute diagnostic agents like Amyvid because we know that each dose can aid our customers in the evaluation of patients."

If you would like me to include any industry news relevant for nuclear pharmacists, please e mail to hayes@nuclearpharmacyjob.com.

 

Advertise With Us | About Us | FAQs | Terms of Use | Privacy policy | Blog | News | Contact Us
© 2008 NuclearPharmacy